Key Stats for Embecta Stock
- 2-Day Price Change for Embecta stock: -20%
- $EMBC Share Price as of Nov. 26: $12.57
- 52-Week High: $21.48
- $EMBC Stock Price Target: $16.67
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Embecta (EMBC) stock dipped over 12% on Wednesday despite the diabetes care products maker beating earnings expectations for its fiscal fourth quarter 2025.
The medical device company reported earnings per share of $0.50, topping the analyst estimate of $0.46. However, revenue came in at $263.30 million, slightly missing the consensus estimate of $265.66 million.
The quarter was challenging for the company, as revenue declined 8% year-over-year on a reported basis and 10.4% on an adjusted, constant-currency basis.
U.S. revenue totaled $142 million, down 15.2% year-over-year on an adjusted constant currency basis, while international revenue reached $122 million, declining 4% on the same basis.
The U.S. revenue decline was driven by several factors as the company faced a tough comparison to the prior year’s fourth quarter, which benefited from approximately $10 million in additional distributor orders ahead of a then-looming port strike.
The business also saw an unwinding of favorable order timing from the July 4 holiday that boosted Q3 results by about $7 million. Additionally, pricing headwinds totaled roughly $7 million, primarily due to milestone payments made to a large U.S. pharmacy customer.
International weakness centered on China, where heightened competitive intensity and growing preference for local Chinese brands amid evolving U.S.-China geopolitical tensions pressured results.
CEO Dev Kurdikar noted that China performed in line with expectations for Q4, and the company has taken steps to stabilize the situation, including reorganizing its sales team and introducing a more price-competitive pen needle with lower manufacturing costs.
See analysts’ growth forecasts and price targets for EMBC stock (It’s free!) >>>
What the Market Is Telling Us About EMBC Stock
The pressure on Embecta stock reflects investor concern about the company’s fiscal 2026 outlook, which calls for revenue to be flat to down 2% on an adjusted constant currency basis.
On a reported basis, revenue is expected to range from $1.071 billion to $1.093 billion, representing a decline of 0.9% to growth of 1.1%.
Management expects the adjusted operating margin to be between 29% and 30%, down approximately 180 basis points at the midpoint from fiscal 2025 levels.
About half of this decline stems from higher cannula costs, as the company currently sole-sources these components from its former parent company, BD, under an agreement running through 2032.
The other half reflects rising R&D expenses, which are now approximately 2% of revenue, as Embecta invests in market-appropriate pen needles and syringes while qualifying alternative cannula suppliers.
Embecta did provide some bright spots, generating approximately $182 million in free cash flow during fiscal 2025 and paying down roughly $184 million in debt, exceeding its original target of $110 million.
Net leverage now sits at 2.9x net debt to adjusted EBITDA, creating financial flexibility for potential organic and inorganic growth opportunities.
Management also highlighted meaningful progress on its GLP-1 strategy during the quarter. The company is now collaborating with more than 30 pharmaceutical partners to co-package pen needles with generic GLP-1 therapies.
Several partners have already signed agreements and placed purchase orders, with products included in multiple regulatory submissions expected to lead to commercial launches.
Generic GLP-1 partners are anticipating launches in Canada, Brazil, and India during calendar year 2026, though Embecta doesn’t control the timing of regulatory submissions or approvals.
Looking ahead, fiscal 2026 guidance assumes modest volume declines in the core injection business and negligible-to-positive contributions from new revenue streams, such as GLP-1 partnerships, depending on whether results land at the high or low end of the range.
Management expects to generate between $180 million and $200 million in free cash flow for fiscal 2026, keeping the company on track with its Analyst Day commitment to generate approximately $600 million in cumulative free cash flow from fiscal 2026 through 2028.
Embecta stock slid on cautious fiscal 2026 guidance despite solid debt-reduction progress and advancing GLP-1 partnerships. Investors appear focused on near-term margin pressures and revenue headwinds rather than the company’s longer-term strategic positioning in the emerging generic GLP-1 market.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Embecta Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
